NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alimera Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.54 +0.14 (+1.89 %) (As of 01/27/2020 07:50 AM ET) Add Compare Today's Range$7.22Now: $7.54▼$7.6850-Day Range$6.56MA: $7.37▼$9.5752-Week Range$2.96Now: $7.54▼$18.15Volume20,849 shsAverage Volume58,574 shsMarket Capitalization$37.47 millionP/E RatioN/ADividend YieldN/ABeta2.09 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALIM Previous Symbol CUSIPN/A CIK1267602 Webhttp://www.alimerasciences.com/ Phone678-990-5740Debt Debt-to-Equity RatioN/A Current Ratio1.97 Quick Ratio1.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$46.97 million Price / Sales0.80 Cash FlowN/A Price / Cash FlowN/A Book Value($5.91) per share Price / Book-1.28Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-16,380,000.00 Net Margins-23.40% Return on EquityN/A Return on Assets-23.97%Miscellaneous Employees124 Outstanding Shares4,970,000Market Cap$37.47 million Next Earnings Date2/4/2020 (Estimated) OptionableOptionable Receive ALIM News and Ratings via Email Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ALIM Rates by TradingView Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions What is Alimera Sciences' stock symbol? Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM." When did Alimera Sciences' stock split? How did Alimera Sciences' stock split work? Alimera Sciences's stock reverse split on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split. How were Alimera Sciences' earnings last quarter? Alimera Sciences Inc (NASDAQ:ALIM) posted its earnings results on Tuesday, October, 29th. The biopharmaceutical company reported ($0.60) EPS for the quarter, meeting the consensus estimate of ($0.60). The biopharmaceutical company earned $12.85 million during the quarter, compared to the consensus estimate of $12.75 million. View Alimera Sciences' Earnings History. When is Alimera Sciences' next earnings date? Alimera Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Alimera Sciences. What price target have analysts set for ALIM? 3 equities research analysts have issued 12 month price targets for Alimera Sciences' stock. Their forecasts range from $15.00 to $45.00. On average, they anticipate Alimera Sciences' stock price to reach $30.00 in the next year. This suggests a possible upside of 297.9% from the stock's current price. View Analyst Price Targets for Alimera Sciences. What is the consensus analysts' recommendation for Alimera Sciences? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences. Has Alimera Sciences been receiving favorable news coverage? Media stories about ALIM stock have trended somewhat negative on Monday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Alimera Sciences earned a news impact score of -1.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Alimera Sciences. Are investors shorting Alimera Sciences? Alimera Sciences saw a drop in short interest in January. As of January 15th, there was short interest totalling 74,100 shares, a drop of 17.5% from the December 31st total of 89,800 shares. Based on an average daily volume of 71,100 shares, the short-interest ratio is presently 1.0 days. Currently, 1.9% of the company's stock are sold short. View Alimera Sciences' Current Options Chain. Who are some of Alimera Sciences' key competitors? Some companies that are related to Alimera Sciences include Selecta Biosciences (SELB), AcelRx Pharmaceuticals (ACRX), Verastem (VSTM), TapImmune (MRKR), Helix Biopharma (HBPCF), Abeona Therapeutics (ABEO), Newron Pharmaceuticals (NWPHF), Menlo Therapeutics (MNLO), REDHILL BIOPHAR/S (RDHL), CymaBay Therapeutics (CBAY), Savara (SVRA), Zynerba Pharmaceuticals (ZYNE), ProMetic Life Sciences (PFSCF), Trillium Therapeutics (TRIL) and vTv Therapeutics (VTVT). What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Agenus (AGEN), Opko Health (OPK), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), CorMedix (CRMD), Aldeyra Therapeutics (ALDX) and Athersys (ATHX). Who are Alimera Sciences' key executives? Alimera Sciences' management team includes the folowing people: Mr. Charles Daniel Myers, Non-Exec. Chairman & Consultant (Age 65)Mr. Richard S. Eiswirth Jr., Pres, CEO & Director (Age 51)Dr. Kenneth Green, Consultant (Age 61)Mr. David R. Holland, Co-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets (Age 55)Mr. J. Philip Jones, Chief Financial Officer (Age 55) How do I buy shares of Alimera Sciences? Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Alimera Sciences' stock price today? One share of ALIM stock can currently be purchased for approximately $7.54. How big of a company is Alimera Sciences? Alimera Sciences has a market capitalization of $37.47 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.View Additional Information About Alimera Sciences. What is Alimera Sciences' official website? The official website for Alimera Sciences is http://www.alimerasciences.com/. How can I contact Alimera Sciences? Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected] MarketBeat Community Rating for Alimera Sciences (NASDAQ ALIM)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 316 (Vote Outperform)Underperform Votes: 312 (Vote Underperform)Total Votes: 628MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe ALIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALIM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/27/2020 by MarketBeat.com StaffFeatured Article: What is meant by buying and selling pressure?
